Journal
CURRENT OPINION IN IMMUNOLOGY
Volume 47, Issue -, Pages 57-63Publisher
CURRENT BIOLOGY LTD
DOI: 10.1016/j.coi.2017.07.003
Keywords
-
Categories
Funding
- National Cancer Institute of the National Institutes of Health [R01CA157303]
- Georgia Cancer Center
- Georgia Research Alliance (GRA)
Ask authors/readers for more resources
Recent advances in cancer immunology, such as the discovery of immune checkpoint inhibitors, have validated immune cells as potential key players for effective cancer treatment. The efficacy of these therapies seems to be codependent on a tumor-reactive T lymphocyte response. For many years, numerous attempts and strategies in developing vaccines to generate tumor-reactive T cells have yielded poor results in the clinic due to suboptimal immunogenicity and the inability to overcome an immunosuppressive tumor microenvironment. In this review, we summarize past and current advances in T cell vaccines and describe our experience in developing optimized methods for antigen/adjuvant selection and vaccine administration in order to induce powerful anti-tumor responses.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available